Levetiracetam + Oxcarbazepine

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Jun 1, 2011 โ†’ Jul 1, 2014

About Levetiracetam + Oxcarbazepine

Levetiracetam + Oxcarbazepine is a approved stage product being developed by UCB for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT01498822. Target conditions include Epilepsy.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01498822ApprovedCompleted

Competing Products

20 competing products in Epilepsy

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
52
LacosamideUCBPhase 3
74
Zonisamide + PlaceboEisaiPhase 3
77
ZonegranEisaiApproved
85
perampanel + perampanelEisaiPhase 1
33
Perampanel + PlaceboEisaiApproved
85
perampanelEisaiApproved
85
E2007 + PlaceboEisaiPhase 2
52
Placebo + RufinamideEisaiPhase 3
77
E2007 (perampanel) + PlaceboEisaiPhase 2
52
Perampanel Oral TabletEisaiApproved
85
perampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
Zonisamide + CarbamazepineEisaiPhase 3
77
PerampanelEisaiApproved
85
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
33
PerampanelEisaiPhase 2
52
Zonisamide + PlaceboEisaiPhase 3
77
zonisamide low dose group + zonisamide high dose groupEisaiApproved
85
E2007 + E2007 + PlaceboEisaiPhase 2
52